N
11.95
0.49 (4.28%)
| Previous Close | 11.46 |
| Open | 11.43 |
| Volume | 1,991,250 |
| Avg. Volume (3M) | 1,617,795 |
| Market Cap | 1,338,184,704 |
| Price / Sales | 2.05 |
| Price / Book | 4.03 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | -24.43% |
| Diluted EPS (TTM) | -1.51 |
| Quarterly Revenue Growth (YOY) | 11.90% |
| Total Debt/Equity (MRQ) | 192.49% |
| Current Ratio (MRQ) | 1.47 |
| Operating Cash Flow (TTM) | -30.46 M |
| Levered Free Cash Flow (TTM) | 16.94 M |
| Return on Assets (TTM) | -8.64% |
| Return on Equity (TTM) | -45.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | NovoCure Limited | Bullish | Bearish |
AIStockmoo Score
1.9
| Analyst Consensus | 5.0 |
| Insider Activity | 2.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.90 |
|
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 9.84% |
| % Held by Institutions | 87.40% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 49.00 (HC Wainwright & Co., 310.04%) | Buy |
| Median | 33.50 (180.34%) | |
| Low | 18.00 (Wedbush, 50.63%) | Hold |
| Average | 33.50 (180.34%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 13.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Feb 2026 | 49.00 (310.04%) | Buy | 13.75 |
| 12 Feb 2026 | 47.00 (293.31%) | Buy | 12.53 | |
| Wedbush | 15 Jan 2026 | 18.00 (50.63%) | Hold | 13.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BEN ARYE BARAK | 13.30 | - | 50,125 | 666,663 |
| BRACKMANN CHRISTOPH | 13.30 | 13.42 | 48,725 | 647,273 |
| CORDOVA ASHLEY | - | 13.42 | -17,638 | -236,702 |
| DOYLE WILLIAM F | 13.30 | 13.30 | 328,397 | 4,367,680 |
| LEONARD FRANK X | 13.30 | 13.42 | 144,393 | 1,919,754 |
| LEUPIN NICOLAS | - | 13.42 | -1,100 | -14,762 |
| PARAVASTHU MUKUND | 13.30 | 13.83 | -3,511 | -87,560 |
| PURI MICHAL NATH | 13.30 | 13.42 | 39,000 | 518,568 |
| WEINBERG URI | 13.30 | 13.42 | 43,713 | 580,613 |
| Aggregate Net Quantity | 632,104 | |||
| Aggregate Net Value ($) | 8,361,527 | |||
| Aggregate Avg. Buy ($) | 13.30 | |||
| Aggregate Avg. Sell ($) | 13.50 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PARAVASTHU MUKUND | Officer | 05 Mar 2026 | Sell (-) | 43,246 | 14.23 | 615,391 |
| PURI MICHAL NATH | Officer | 04 Mar 2026 | Sell (-) | 1,100 | 13.42 | 14,762 |
| PARAVASTHU MUKUND | Officer | 04 Mar 2026 | Sell (-) | 5,377 | 13.42 | 72,159 |
| LEONARD FRANK X | Officer | 04 Mar 2026 | Sell (-) | 5,607 | 13.42 | 75,246 |
| BRACKMANN CHRISTOPH | Officer | 04 Mar 2026 | Sell (-) | 6,412 | 13.42 | 86,049 |
| WEINBERG URI | Officer | 04 Mar 2026 | Sell (-) | 6,412 | 13.42 | 86,049 |
| CORDOVA ASHLEY | Officer | 04 Mar 2026 | Disposed (-) | 17,638 | 13.42 | 236,702 |
| LEUPIN NICOLAS | Officer | 04 Mar 2026 | Sell (-) | 1,100 | 13.42 | 14,762 |
| DOYLE WILLIAM F | Officer | 03 Mar 2026 | Acquired (+) | 400,284 | 13.30 | 5,323,777 |
| DOYLE WILLIAM F | Officer | 03 Mar 2026 | Sell (-) | 71,887 | 13.30 | 956,097 |
| PURI MICHAL NATH | Officer | 03 Mar 2026 | Acquired (+) | 40,100 | 13.30 | 533,330 |
| PARAVASTHU MUKUND | Officer | 03 Mar 2026 | Acquired (+) | 45,112 | 13.30 | 599,990 |
| LEONARD FRANK X | Officer | 03 Mar 2026 | Acquired (+) | 150,000 | 13.30 | 1,995,000 |
| BRACKMANN CHRISTOPH | Officer | 03 Mar 2026 | Acquired (+) | 55,137 | 13.30 | 733,322 |
| WEINBERG URI | Officer | 03 Mar 2026 | Acquired (+) | 50,125 | 13.30 | 666,663 |
| BEN ARYE BARAK | Officer | 03 Mar 2026 | Acquired (+) | 50,125 | 13.30 | 666,663 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update |
| 22 Dec 2025 | Announcement | Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |